Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Characterization of Ubrogepant: A Potent and Selective Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor.

Autor: Moore E; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Fraley ME; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Bell IM; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Burgey CS; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., White RB; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Li CC; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Regan CP; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Danziger A; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Stranieri Michener M; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Hostetler E; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Banerjee P; Allergan plc pradeep.banerjee@allergan.com., Salvatore C; Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.

Publikováno v: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2020 Jan 28. Date of Electronic Publication: 2020 Jan 28.